WHA72: Portuguese Minister of Health, Marta Temido, underscores strong support for the WHO transparency resolution

On Monday, 20 May 2019, the Republic of Korea, Italy, Costa Rica, Greece, Indonesia, Italy, Mexico, Mongolia, Netherlands, Portugal, Republic of Korea, Saudi Arabia, Spain, and Vietnam convened an official side event at the 72nd session of the World Health… Continue Reading

24 May 2019 – KEI panel discussion – Assessing the implications of the development of new cell and gene-based therapies (including CAR T and CRISPR): What role should WHO play?

On Friday, 24 May 2019, Knowledge Ecology International (KEI) will convene an expert panel, “Assessing the implications of developments in cell and gene-based therapies (including CAR T and CRISPR): What role should WHO should play?” from 12h30 to 14h30 in… Continue Reading

Comparison between April 29, May 7, and May 10 versions of WHA 72 resolution on transparency

On Monday, May 13th, Politico published the latest version (May 10, 2019) of the transparency resolution noting the “dizzying number of brackets” in the latest text. The original sponsors are: Italy, Greece, Malaysia, Portugal, Serbia, Slovenia, South Africa, Spain, Turkey,… Continue Reading

WHO donors in 2018 – US, Gates Foundation, UK, GAVI, Germany, OCHA, and Japan: Setting the Agenda for Global Health?

In advance of the 72nd World Health Assembly (20 May 2019 – 28 May 2019), the World Health Organization (WHO) published a document (A72/INF./5, 9 May 2019) entitled, Voluntary contributions by fund and by contributor, 2018. Total voluntary contributions to… Continue Reading

WIPO Broadcasting Treaty – Paving the way for a right for on-demand streaming services?

In April 2019, the World Intellectual Property Organization (WIPO) published a new version (SCCR/38/10) of the WIPO Treaty for the Protection of Broadcasting Organizations. Currently, the proposed treaty anticipates the scope of application to include new beneficiaries such as on-demand… Continue Reading

UNDP, Unitaid, and WHO caught in Big Pharma’s crosshairs

PhRMA’s Special 301 submissions are part of a yearly ritual to shape the “Special 301” Report, an annual review of the global state of intellectual property rights (IPR) protection and enforcement, conducted by the Office of the United States Trade… Continue Reading